Protect NIH's DNA advisory committee

Zach N. Adelman, Lorraine M. Albritton, Kathleen Boris-Lawrie, Michael J. Buchmeier, Paula Cannon, Mildred Cho, David DiGiusto, J. Kevin Donahue, Howard J. Federoff, Marie Louise Hammarskjold, Angelica D. Hardison, Patrick Hearing, Benhur Lee, Dean Anthony Lee, Matthew H. Porteus, Lainie Friedman Ross, Susan R. Ross, Dawn P. Wooley, Laurie Zoloth

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)409-410
Number of pages2
Issue number6413
StatePublished - Oct 26 2018

Bibliographical note

Funding Information:
The Recombinant DNA Advisory Committee (RAC) was founded at the behest of concerned scientists based on the principle that public trust of advanced technologies must be earned through transparency and expert deliberation. For more than 40 years, the RAC has served as custodian of the National Institutes of Health (NIH) guidelines, with responsibilities in human gene therapy evolving from regulatory to advisory to the NIH and Food and Drug Administration (FDA). However, the NIH director and FDA commissioner have proposed the elimination of RAC review of human gene therapy protocols (1, 2).

Cite this